Skip to Main Content

Paper Details

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Eur Urol
61
2020
ATM, Advanced Prostate Cancer, BRCA1/2, CDK12, CDK12 mutant, CDK12 mutations, CDK12-mutated prostate cancer, Cyclin-dependent Kinase 12 Mutant, Cyclin-dependent kinase 12, HRD, PATIENT, PSA, Patients, TP53, advanced prostate cancer, advanced prostate cancers, androgen, androgen receptor, castration-resistant disease, circulating tumor DNA, high-grade Gleason 8 cancers, homologous recombination deficiency, metastatic cancer, metastatic prostate cancer, patient, patients, prostate cancer, prostate-specific antigen, tumor, tumors
Author NameAffiliation
Melissa A ReimersUniversity of Michigan ann arbor
Marcin CieslikMichigan Center for Translational Pathology, University of Michigan ann arbor
Bruce MontgomeryUniversity of Washington
Alexander W WyattUniversity of British Columbia
Kim N ChiVancouver Cancer Centre, University of British Columbia
Eric J SmallUniversity of California San Francisco, USA Helen Diller Family Comprehensive Cancer Center
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, USA Howard Hughes Medical Institute ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, USA Howard Hughes Medical Institute ann arbor
Felix Y FengUniversity of California San Francisco, USA Helen Diller Family Comprehensive Cancer Center
Jonathan ChouUniversity of California San Francisco, USA Helen Diller Family Comprehensive Cancer Center
  • 1 - 10

Datasets

Release 1.2